Opinion

Video

Perspectives on Long-Standing and Novel Treatments for Dry Eye

Richard Adler, MD, FACS, offers key takeaways from a Case-Based Roundtable discussion that focused on the diagnosis and management of dry eye disease.

Related Videos
EyeCon 2024: Adam Wenick, MD, talks about myopic interventions across the lifespan
Adam Wenick, MD, chairs EyeCon session: New treatments in geographic atrophy from detection to intervention
EyeCon 2024: Key takeaways for enhanced patient care from Day 1
EyeCon 2024: Peter McDonnell, MD, and Laura Periman, MD, on the importance of integrating new knowledge into practice
Arun Gulani, MD: How the Gni instrument enhances precision and control in cataract surgery
EyeCon 2024: Laura M. Periman, MD, shares her passion for dry eye disease, discussing her surprising discovery of the Alpenglow Sign in Demodex blepharitis
David Eichenbaum, MD, presents advances in AMD therapy, highlights different mechanisms with a common goal
1 KOL featured in this series.
1 KOL featured in this series.
Related Content
Aldeyra Therapeutics resubmits New Drug Application for reproxalap for the treatment of dry eye disease
October 3rd 2024

Aldeyra Therapeutics resubmits New Drug Application for reproxalap for the treatment of dry eye disease

Ehsan Sadri, MD, and Colin Green, PhD: How a noninvasive eye drop therapy could transform keratoconus care
September 23rd 2024

Innovation Series: What a noninvasive eye drop approach may mean for the future of keratoconus

Site Logo
September 26th 2024

Las complejidades en la adopción de una nueva tecnología

Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics
August 30th 2024

Latest advances in X-linked retinitis pigmentosa: Optimizing diagnosis and developments in gene therapy

Sonoma Pharmaceuticals, EMC Pharma roll out collaboration to co-market expanded eye care product line
September 11th 2024

Sonoma Pharmaceuticals, EMC Pharma roll out collaboration to co-market expanded eye care product line

FDA confirms acceptability of Palatin's remaining Phase 3 pivotal clinical trials for PL9643 in DED
September 6th 2024

FDA confirms acceptability of Palatin's remaining Phase 3 pivotal clinical trials for PL9643 in DED

© 2024 MJH Life Sciences

All rights reserved.